Bio Bridge Science Inc - Current report filing (8-K)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

July 4, 2008

BIO-BRIDGE SCIENCE, INC.

(Exact name of registrant as specified in its charter)

Delaware		000-51497		20-1802936
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1211 West 22nd Street, Suite 615, Oak Brook, Illinois		60523
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code:

630-928-0869

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

---

 

This Form 8-K and other reports filed by the Registrant from time to time with the Securities and Exchange Commission (collectively the “Filings”) contain forward looking statements and information that are based upon beliefs of, and information currently available to, the Registrant’s management as well as estimates and assumptions made by the Registrant’s management. When used in the Filings the words “anticipate”, “believe”, “estimate”, “expect”, “future”, “intend”, “plan” or the negative of these terms and similar expressions as they relate to the Registrant or the Registrant’s management identify forward looking statements. Such statements reflect the current view of the Registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the Registrant’s industry, operations and results of operations and any businesses that may be acquired by the Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Item 8.01 Other Events

 

As used in this report, "we", "us", "our" or "BGES" refer to Bio-Bridge Science, Inc., a Delaware corporation and its subsidiaries.

 

On July 4, Bio-Bridge Science Inc. received a certificate of approval from Department of Commerce of Inner Mongolia Autonomous Region of the PRC for approving the acquisition of Xinheng Baide Biotechnology Co. Ltd. The Company has one month from the approval date to close the transaction and obtain a new business license. The transaction is expected to close before the end of July.

Item 9.01 Financial Statements and Exhibits

 

(c) Exhibits.

 

Exhibit Number		Description
99.1		Press release dated July 8, 2008

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

			BIO-BRIDGE SCIENCE, INC.
Date:  July 8, 2008	By:		/s/ Liang Qiao, MD.
	Name:		Liang Qiao, MD.
	Title:		Chief Executive Officer

 

 

 

---